| Filed On | Filing |
|---|---|
| 16 Nov 2026 | FORM 10-Q |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
FDA Fast Track Designation for Plinabulin plus docetaxel marks key regulatory milestone in DUBLIN-4 study population of Post-ICI Non-Squamous NSCLC with no actionable genomic alteration (AGA) |
| 29 Oct 2026 | SCHEDULE 13G/A |
| 13 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
BeyondSpring Inc. (the “Company”) held its 2026 annual meeting of shareholders on October 13, 2026. A total of 20,905,921 of the Company’s ordinary shares were present or represented by proxy at the meeting, representing approximately 50... |
| 06 Oct 2026 |
8-K: Completion of Acquisition or Disposition of Assets
On September 28, 2026, BeyondSpring Inc. (“BYSI” or the “Company”) entered into a Share Purchase and Collaboration Agreement (the “Agreement”) with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”), a majority-owned indirect subsidiary ... |
| 02 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 29, 2026, BeyondSpring Inc. (the “Company”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the Company’s market value ... |
| 29 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
THIS SHARE PURCHASE AND COLLABORATION AGREEMENT (this “Agreement”), dated as of September 28, 2026, is made by and among BeyondSpring Inc., an exempted company incorporated and existing with limited liability under the laws of The Cayman... |
| 29 Sep 2026 | 424B5 |
| 18 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 17, 2026, BeyondSpring Inc. (the “Company”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s ordinary ... |
| 03 Sep 2026 | FORM DEFA14A |
| 03 Sep 2026 | DEFINITIVE PROXY STATEMENT |
| 03 Sep 2026 | ARS |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | FORM 10-Q |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy |
| 06 Jul 2026 |
Form 4: Majeti Jiangwen, Director
Granted 100,000 Stock Options (right to buy) |
| 06 Jul 2026 |
Form 4: Qiu Min, Chief Executive Officer
Granted 100,000 Stock Options (right to buy) |
| 06 Jul 2026 |
Form 3: Qiu Min, Chief Executive Officer
Holds 2,498 shares of Ordinary Shares |
| 06 Jul 2026 |
Form 3: Li Na (NL), Chief Financial Officer
No securities owned |
| 29 Jun 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In connection with the previously disclosed appointment of Mr. Qiu as Chief Executive Officer, the Company has entered into an employment agreement with Mr. Qiu providing for the compensation described below. |
Loading...